WANBANGDE PHARMACEUTICAL HOLDING GROUP CO., LTD. Financials Wanbangde Pharmaceutical Holding Group Co., Ltd.
Equities
002082
CNE000001P94
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.08 CNY | -0.59% |
|
-0.39% | -20.62% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 1,756 | 2,249 | 8,470 | 9,082 | 5,409 | 3,915 |
| Enterprise Value (EV) 1 | 1,793 | 2,302 | 9,771 | 9,013 | 5,805 | 4,664 |
| P/E ratio | 21.1 x | 16 x | 29.1 x | 54.8 x | 58.8 x | 80 x |
| Yield | - | 1.59% | 1.46% | - | 1.36% | 1.25% |
| Capitalization / Revenue | 0.12 x | 2.51 x | 0.62 x | 4.7 x | 3.03 x | 2.54 x |
| EV / Revenue | 0.13 x | 2.57 x | 0.71 x | 4.67 x | 3.25 x | 3.02 x |
| EV / EBITDA | 7.87 x | 7.58 x | 18 x | 29.6 x | 17.3 x | 28.7 x |
| EV / FCF | -53.4 x | -57.8 x | -27.6 x | 11.1 x | -15.5 x | 106 x |
| FCF Yield | -1.87% | -1.73% | -3.62% | 9.03% | -6.43% | 0.95% |
| Price to Book | 1.18 x | 2.5 x | 3.23 x | 3.5 x | 2.01 x | 1.47 x |
| Nbr of stocks (in thousands) | 238,000 | 238,000 | 618,223 | 614,084 | 613,223 | 611,689 |
| Reference price 2 | 7.380 | 9.450 | 13.70 | 14.79 | 8.820 | 6.400 |
| Announcement Date | 19-03-29 | 20-04-28 | 21-04-27 | 22-04-13 | 23-04-25 | 24-04-25 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 14,335 | 896.4 | 13,702 | 1,931 | 1,786 | 1,542 |
| EBITDA 1 | 227.8 | 303.6 | 543.6 | 304.3 | 335.5 | 162.5 |
| EBIT 1 | 158.7 | 265.4 | 438.1 | 210.7 | 232.6 | 70.19 |
| Operating Margin | 1.11% | 29.61% | 3.2% | 10.91% | 13.02% | 4.55% |
| Earnings before Tax (EBT) 1 | 143.2 | 249.5 | 347.8 | 361.1 | 100.1 | 29.93 |
| Net income 1 | 84.08 | 210.8 | 284.9 | 166.5 | 93.88 | 49.21 |
| Net margin | 0.59% | 23.51% | 2.08% | 8.62% | 5.26% | 3.19% |
| EPS 2 | 0.3500 | 0.5900 | 0.4700 | 0.2700 | 0.1500 | 0.0800 |
| Free Cash Flow 1 | -33.58 | -39.83 | -353.9 | 813.6 | -373.4 | 44.08 |
| FCF margin | -0.23% | -4.44% | -2.58% | 42.14% | -20.9% | 2.86% |
| FCF Conversion (EBITDA) | - | - | - | 267.4% | - | 27.13% |
| FCF Conversion (Net income) | - | - | - | 488.6% | - | 89.57% |
| Dividend per Share | - | 0.1500 | 0.2000 | - | 0.1200 | 0.0800 |
| Announcement Date | 19-03-29 | 20-04-28 | 21-04-27 | 22-04-13 | 23-04-25 | 24-04-25 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 36.8 | 52.6 | 1,301 | - | 397 | 749 |
| Net Cash position 1 | - | - | - | 69.5 | - | - |
| Leverage (Debt/EBITDA) | 0.1616 x | 0.1734 x | 2.393 x | - | 1.183 x | 4.612 x |
| Free Cash Flow 1 | -33.6 | -39.8 | -354 | 814 | -373 | 44.1 |
| ROE (net income / shareholders' equity) | 7.53% | 25.9% | 10.3% | 5.75% | 2.67% | 0.94% |
| ROA (Net income/ Total Assets) | 4.01% | 13.7% | 5.08% | 2.62% | 3.39% | 1.03% |
| Assets 1 | 2,096 | 1,543 | 5,605 | 6,344 | 2,773 | 4,776 |
| Book Value Per Share 2 | 6.270 | 3.780 | 4.240 | 4.230 | 4.380 | 4.340 |
| Cash Flow per Share 2 | 2.090 | 0.5500 | 0.9300 | 1.490 | 0.7600 | 0.3700 |
| Capex 1 | 200 | 113 | 559 | 286 | 167 | 129 |
| Capex / Sales | 1.39% | 12.6% | 4.08% | 14.79% | 9.36% | 8.35% |
| Announcement Date | 19-03-29 | 20-04-28 | 21-04-27 | 22-04-13 | 23-04-25 | 24-04-25 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -20.62% | 430M | |
| +21.55% | 44.12B | |
| +22.18% | 22.61B | |
| +18.22% | 15.11B | |
| +13.74% | 13.61B | |
| +60.91% | 13.34B | |
| -9.24% | 6.94B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +15.65% | 5.75B |
- Stock Market
- Equities
- 002082 Stock
- Financials Wanbangde Pharmaceutical Holding Group Co., Ltd.
